PR84594

SAN DIEGO, June 30, 2020 /PRNewswire=KYODO JBN/ --

Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of

biopharmaceutical contract development and manufacturing services, is pleased

to announce the launch of AJILITY(TM), a flexible and agile drug product

manufacturing platform, designed to advance vaccines and therapies to market by

minimizing time to production.

Logo - https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg

Aji Bio-Pharma's AJILITY platform is designed for novel therapeutics/vaccines

and existing drug products with a new indication that can be used in COVID-19

trials, FDA Emergency Use Authorizations (EUA), or other programs, providing

enhanced flexibility by leveraging our existing, streamlined project

configurations.  With Aji Bio-Pharma's AJILITY, clients will have access to our

experience and expertise to guide them through decisions from components and

excipients to method qualifications. The goal of the AJILITY platform is to

minimize variables during tech transfer, manufacturing and shipping processes

and rely on our regulatory expertise to navigate traditional production hurdles

to quickly get therapies to clinics.  

"The AJILITY platform offers flexibility and time savings, which is an enormous

boost those clients with drug products that need to get to clinical trials

quickly," said Dustin Campbell, Associate Director of Commercial Operations at

Ajinomoto Bio-Pharma Services. "As a leading CDMO for drug product

manufacturing, we understand that some program details affect the manufacturing

timeline more than others. The AJILITY platform utilizes Aji Bio-Pharma's

extensive experience in manufacturing and regulatory insight to fast track our

clients' programs to market."

"We are excited to introduce the AJILITY platform to our client base interested

in our progressive partnering approach to advance their therapeutic to

patients," said Kristin DeFife, Ph.D., Sr. VP of Operations & Site Head at

Ajinomoto Bio-Pharma Services. "The AJILITY platform was developed by a

cross-functional departmental team to provide our clients access to preferred

drug product manufacturing processes, coupled with our expertise in regulatory

submissions, process development, and shipping configurations at our San Diego,

California facility."

To learn more about the AJILITY program, visit: www.AjiBio-Pharma.com/AJILITY.

About Ajinomoto Bio-Pharma Services

Ajinomoto Bio-Pharma Services is a fully integrated contract development and

manufacturing organization with sites in Belgium, United States, Japan, and

India, providing comprehensive development, cGMP manufacturing, and aseptic

fill finish services for small and large molecule APIs and intermediates.

Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and

capabilities for pre-clinical and pilot programs to commercial quantities,

including Corynex(R) protein expression technology, oligonucleotide synthesis,

antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis,

continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is

dedicated to providing a high level of quality and service to meet our client's

needs. Learn more: www.AjiBio-Pharma.com

SOURCE: Ajinomoto Bio-Pharma Services

CONTACT: info@US.AjiBio-Pharma.com